In fact, Ezh2 overexpression or gain of function mutations are known to be associated with several aggressive human solid tumour types, including prostate cancer, breast cancer, and different types of lymphomas, and are indicators of poor prognosis in patients [56–58]. This evidence concerns the gene EZH2 and prostate cancer.